PRVA250117C55000
- 0.30
- 0.000.00%
Privia Health Newsroom
Macquarie Initiates Privia Health(PRVA.US) With Buy Rating, Announces Target Price $25
Macquarie Initiates Coverage On Privia Health Gr With Outperform Rating, Announces Price Target of $25
Privia Health Group, Inc.'s (NASDAQ:PRVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Privia Health Group Insiders Placed Bullish Bets Worth US$9.31m
Privia Health Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains Privia Health(PRVA.US) With Buy Rating, Raises Target Price to $28
Buy-rated Stocks With Passive and Active Net Buying Tailwinds – Citi
We Think You Can Look Beyond Privia Health Group's (NASDAQ:PRVA) Lackluster Earnings
Privia Health Group: Strong Performance and Growth Potential Justifies Buy Rating
Stifel Nicolaus Sticks to Its Buy Rating for Privia Health Group (PRVA)
A Quick Look at Today's Ratings for Privia Health(PRVA.US), With a Forecast Between $25 to $29
Privia Health Group, Inc. (PRVA) Q3 2024 Earnings Call Transcript Summary
Privia Health Group, Inc. (PRVA) Q3 2024 Earnings Call Transcript
Privia Health Is Maintained at Equal-Weight by Barclays
Truist Securities Maintains Buy on Privia Health Gr, Raises Price Target to $27
Privia Health Gr Analyst Ratings
A Quick Look at Today's Ratings for Privia Health(PRVA.US), With a Forecast Between $22 to $28
Express News | Privia Health Group Inc : Barclays Raises Target Price to $21 From $19
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
Robust Growth and Strategic Expansion Drive 'Buy' Rating for Privia Health Group